Onego Bio, a company that makes non-animal egg protein using precision fermentation, has unveiled a new series called “The Power of Trichoderma reesei: Building the Future with Fungi.” This series will showcase the potential of Trichoderma reesei, the fungus used in Onego’s Bioalbumen® protein, by reflecting its scientific strengths, ability to scale in industry, as well as practical applications in food manufacturing.
The first session, called “Why Trichoderma reesei is Precision Fermentation’s Quiet Workhorse,” will be conducted on December 18, 2025. It will feature Dr. Sharief Barends, Head of Research Leiden (Netherlands) and Head of Fungal Genetics at IFF, and Dr. Christopher Landowski, Co-Founder and CTO at Onego Bio. They will discuss about the strong factors of Trichoderma reesei, its role in exact fermentation, as well as how it compares to other microbial platforms. A white paper will be released later with more details about its unique abilities in protein production.
The series will continue with more sessions covering topics such as manufacturing, economics, food applications, etc., including:
- Session 2 (January 2026): Featuring Dr. Marshall Bredwell, Chief Operating Officer at Perfect Day, and Arni Kujala, Onego Bio’s Head of Manufacturing, aiming on the benefits of Trichoderma reesei in targeting protein production as well as other ingredients.
- Session 3 (February 2026): Covering market economics as well as supply chain resilience, with insights from Onego’s CFO, Tom Ferguson.
- Session 4 (March 2026): A live cooking demonstration of Bioalbumen®, Onego’s non-animal egg protein, showcasing how it results in real-world food applications such as whipping, binding, and emulsifying.
According to coherent market insights, the Biotechnology Market is expected to grow at a CAGR of 12.3% during 2025 to 2032. Currently, the market is at USD 1,034.63 Bn in 2025 and is expected to be around USD 2,330.47 Bn by 2032. Increasing prevalence of chronic diseases, new product launches, and strategies like mergers, acquisitions, and collaboration are expected to drive the global biotechnology market growth over the forecast period.
“This series is about shining a light on the platform at the heart of scalable protein innovation,” said Maija Itkonen, Co-Founder and CEO of Onego Bio. “Trichoderma reesei has quietly powered industries for decades, but its full potential in food is still underappreciated. We believe it’s one of the most efficient and underleveraged tools in the fermentation toolbox, and it’s time the world saw what it can do for food.”
Source:
Press Release: Onego Bio
Company: Onego Bio
